WO2012053758A3 - 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물 - Google Patents
실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물 Download PDFInfo
- Publication number
- WO2012053758A3 WO2012053758A3 PCT/KR2011/007441 KR2011007441W WO2012053758A3 WO 2012053758 A3 WO2012053758 A3 WO 2012053758A3 KR 2011007441 W KR2011007441 W KR 2011007441W WO 2012053758 A3 WO2012053758 A3 WO 2012053758A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treating
- liver diseases
- pharmaceutical composition
- active ingredient
- alcoholic liver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물에 관한 것으로, 특히 상기 실로스타졸은 TNF-α 및 지방산 합성 효소인 FAS 유전자의 발현 수준을 농도의존적으로 억제할 뿐 아니라, 카스파제-3 활성을 유의적으로 억제함으로써 종래 알코올성 간염 치료제로 사용되어 오던 펜톡시필린보다 탁월한 알코올성 간질환, 특히 알코올성 간염 치료 또는 예방 효과를 나타내므로, 알코올성 간염 치료 또는 예방용 약제로서 유용하게 이용될 수 있다.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/880,792 US20130267558A1 (en) | 2010-10-22 | 2011-10-07 | Pharmaceutical composition for treating or preventing alcoholic liver diseases, containing cilostazol as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0103656 | 2010-10-22 | ||
KR1020100103656A KR101094934B1 (ko) | 2010-10-22 | 2010-10-22 | 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012053758A2 WO2012053758A2 (ko) | 2012-04-26 |
WO2012053758A3 true WO2012053758A3 (ko) | 2012-06-14 |
Family
ID=45506428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/007441 WO2012053758A2 (ko) | 2010-10-22 | 2011-10-07 | 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20130267558A1 (ko) |
KR (1) | KR101094934B1 (ko) |
WO (1) | WO2012053758A2 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3220901B1 (en) | 2014-11-20 | 2020-02-19 | VIB vzw | Means and methods for treatment of early-onset parkinson's disease |
US10588906B2 (en) * | 2017-08-08 | 2020-03-17 | Seoul National University Hospital | Method of preventing hair loss or promoting hair growth by using phosphodiesterase 3 inhibitor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003061648A1 (en) * | 2002-01-25 | 2003-07-31 | Diamedica Inc. | Use of cholinesterase antagonists to treat insulin resistance |
WO2009008539A1 (en) * | 2007-07-11 | 2009-01-15 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives including cilostazol for treating fatty liver |
-
2010
- 2010-10-22 KR KR1020100103656A patent/KR101094934B1/ko not_active IP Right Cessation
-
2011
- 2011-10-07 WO PCT/KR2011/007441 patent/WO2012053758A2/ko active Application Filing
- 2011-10-07 US US13/880,792 patent/US20130267558A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003061648A1 (en) * | 2002-01-25 | 2003-07-31 | Diamedica Inc. | Use of cholinesterase antagonists to treat insulin resistance |
WO2009008539A1 (en) * | 2007-07-11 | 2009-01-15 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives including cilostazol for treating fatty liver |
Non-Patent Citations (1)
Title |
---|
FUJITA K. ET AL.: "Effectiveness of antiplatelet drugs against experiemental non-aoholic fatty liver disease", GUT, vol. 57, no. 11, 2008, pages 1583 - 1591 * |
Also Published As
Publication number | Publication date |
---|---|
KR101094934B1 (ko) | 2011-12-15 |
WO2012053758A2 (ko) | 2012-04-26 |
US20130267558A1 (en) | 2013-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014005013A3 (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
WO2017059223A3 (en) | Compositions and methods for inhibiting gene expression of lpa | |
PH12016500216B1 (en) | Stable pharmaceutical composition and methods of using same | |
WO2009105774A3 (en) | Amino acid inhibitors of cytochrome p450 | |
MX2012012438A (es) | Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina. | |
WO2010150995A3 (en) | Compositions for treating drug addiction and improving addiction-related behavior | |
WO2010032140A3 (en) | Pharmaceutical compositions and related methods of delivery | |
MX2012003555A (es) | Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma. | |
WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
WO2011051354A3 (en) | Transdermal pharmaceutical compositions comprising active agents | |
WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
PH12014501620A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
WO2012162439A3 (en) | Compositions comprising fusidic acid and packages therefor | |
WO2011159129A3 (ko) | 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물 | |
PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
WO2009045053A3 (en) | A cancer sensitizer comprising chlorogenic acid | |
WO2012085249A3 (en) | Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid | |
WO2016108572A3 (ko) | 콜레스테롤 관련 질환의 예방 및 치료용 조성물 | |
WO2012053758A3 (ko) | 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물 | |
WO2011058245A8 (fr) | Nouveaux derives de mannopyranoside ayant une activite anticancereuse | |
WO2011103920A3 (en) | Pharmaceutical or neutraceutical formulation | |
WO2012077968A3 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
WO2013162298A8 (ko) | 신규한 베타 알라닌 유도체, 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 약제학적 조성물 | |
WO2012029076A3 (en) | Stable pharmaceutical composition | |
EP2636677A4 (en) | CDK-HEMMENDES PYRROLOPYRIMIDINONCARBOXAMID DERIVATIVE OR PHARMACEUTICAL ACCEPTABLE SALT AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEREOF FOR THE PREVENTION OR TREATMENT OF LIVER CELL CARCINOMA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11834558 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13880792 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11834558 Country of ref document: EP Kind code of ref document: A2 |